Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | LIPE | Q05469 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | CYP7A1 | P22680 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | OTUD7B | Q6GQQ9 | 2/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PKLR | P30613 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2637431 | 0.94 | MEN1 (0.45) | MEN1KMT2ALIPESCN9ACYP11B1 | |
| SCHEMBL2637626 | 0.87 | MEN1 (0.54) | MEN1KMT2ALIPEPRCP | |
| SCHEMBL2635298 | 0.87 | KDM2B (0.41) | MEN1KMT2ASCN9ACYP11B1KDM2B | |
| SCHEMBL2637346 | 0.87 | KDM2B (0.42) | MEN1KMT2AKDM2BLMNATSHR | |
| SCHEMBL2637598 | 0.84 | HTT (0.54) | MEN1KMT2ALMNAPKMPKLR | |
| SCHEMBL2635565 | 0.83 | KDM2B (0.41) | MEN1KMT2ASCN9ACYP11B1KDM2B | |
| SCHEMBL2637344 | 0.83 | S100A9 (0.43) | MEN1KMT2ALIPEMAPK1PRCP | |
| SCHEMBL2637735 | 0.81 | MEN1 (0.52) | MEN1KMT2ALIPEPRCP | |
| SCHEMBL25145662 | 0.81 | PKM (0.55) | MEN1KMT2ALIPESCN9ACYP11B1 | |
| SCHEMBL2637657 | 0.81 | KDM2B (0.41) | MEN1KMT2AKDM2BLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116270-A1 | NOVEL COMPOUNDS | CONVERGENCE PHARMACEUTICALS LIMTED | 2013-05-09 | — | — | US | claimed |
| EP-2569318-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-03-20 | — | — | EP | claimed |
| WO-2011141729-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2011-11-17 | — | — | WO | claimed |
| US-20130116270-A1 | NOVEL COMPOUNDS | CONVERGENCE PHARMACEUTICALS LIMTED | 2013-05-09 | — | — | US | disclosed |
| US-20130116270-A1 | NOVEL COMPOUNDS | CONVERGENCE PHARMACEUTICALS LIMTED | 2013-05-09 | — | — | US | disclosed |
| US-20130116270-A1 | NOVEL COMPOUNDS | CONVERGENCE PHARMACEUTICALS LIMTED | 2013-05-09 | — | — | US | disclosed |
| EP-2569318-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011141729-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141729-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116270-A1 | NOVEL COMPOUNDS | TRPV2, CACNA1C, CACNA1B | MEN1 3951/4885KMT2A 4275/4885LIPE 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.